论文部分内容阅读
:[目的]探讨血清CA125在卵巢上皮癌诊疗中的应用价值。[方法]应用放射免疫方法测定165例原发性卵巢上皮癌治疗前血清CA125值 ,对其中87例患者术后3个月内连续性测定 ,观察疗效和CA125变化间的相关性。[结果]卵巢上皮癌CA125检测阳性率80 7% ,尤以浆液性卵巢癌最高94 8%。疗效为完全缓解的29例术后CA125水平较术前明显下降(P<0 001) ,疗效为部分缓解的40例术后CA125值较术前下降(P<0 05) ,疗效为进展的12例术后CA125值较术前升高(P<0 05) ,疗效为无改变的6例手术前后CA125值差异无显著性(P>0 05)。[结论]CA125测定是卵巢上皮癌诊断和监测疗效的有效无创性检查方法
: [Objective] To investigate the clinical value of serum CA125 in the diagnosis and treatment of epithelial ovarian cancer. [Method] The serum CA125 of 165 cases of primary epithelial ovarian cancer before treatment were measured by radioimmunoassay, and 87 cases of them were measured continuously within 3 months after operation to observe the correlation between curative effect and changes of CA125. [Results] The positive rate of CA125 in ovarian epithelial carcinoma was 80.7%, especially the highest in serous ovarian cancer was 94.8%. The curative effect was complete remission in 29 cases of postoperative CA125 levels decreased significantly compared with preoperative (P <0.001), the efficacy of partial remission in 40 cases of postoperative CA125 decreased compared with preoperative (P <0 05), the effect of 12 The postoperative CA125 value was significantly higher than that before operation (P <0.05), and the curative effect was unchanged. There was no significant difference in CA125 between before and after operation (P> 0.05). [Conclusion] The CA125 assay is a valid noninvasive method for the diagnosis and monitoring of ovarian epithelial cancer